print logo

Contact Our Offices

Clinical Trials

Reset Text Size: A A A

Dry Age Related Macular Degeneration

Active Studies

BEACON (Allergan)

A 2 year, phase 2 study on the safety and efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with geography atrophy secondary to age-related macular degeneration.

OMASPECT (Genentech)

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a roche-sponsored study.

SPECTRI (Genentech)

A 2 year, phase 3, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.

TARGETing GA (Santen Inc.)

Non-interventional, cross-sectional study of Alu RNA measurement and complement factor genotyping of single nucleotide polymorphisms in the complement pathway in patients with geographic atrophy associated with dry age-related macular degeneration.

Completed Studies

ICON (Pfizer)

A 1 year Phase 2 study examining a monoclonal antibody to decrease the amount of drusen in the eyes seen in people with Dry AMD with an intravenous infusion.

PREVENT IIT (NCRVA & Genentech)

A 2 year investigator initiated study on prophylactic Ranibizumab for exudative age-related macular degeneration (AMD) in vulnerable eyes with Non exudative AMD Trial.

SEATTLE (Acucela)

A 2 year Phase 2/3 study which aims to reduce the rate of Dry AMD progression with the use of an pill.